← Leaderboards
Amit J. Sabnis
University Of California, San Francisco
$2,108,153
Attributed
$2,108,153
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $482.3K · FY2018–25$500K$375K$250K$125K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,108,153 · 2
By mechanism
K08$1,143,695 · 1
R01$964,458 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Rahul Aggarwal$5,953,056
- Daniel B Vigneron$43,424,992
- Hong-Yu Li$3,813,256
- Neil P Shah$6,146,823
- Nadia R Roan$13,619,124
Others in their field
Other Emerging Leaders on “Response”
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$195,683,539
- Kimberly Smith · Ppd Development Lp$115,671,664
- Paul F Gallagher · Woods Hole Oceanographic Institution$92,619,872
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Ted Ross · University Of Georgia$70,992,558
Research focus
ResponsePre-Clinical ModelGeneticProteinsTherapeutic TargetClinical TrialsDependenceFutureMolecularPreclinical TrialRhabdomyosarcomaBiologicalTranslatingTranslationsCellsChildChemotherapyCancer CellMalignant Childhood NeoplasmMalignant NeoplasmsOncogenesBiologyBiological MarkersAuthorship
Grant awards (7)
Targeting mTORC1 translational control in FOXO1 fusion positive rhabdomyosarcoma$482,283
R01 · FY2025 · CA · contact PI
Targeting mTORC1 translational control in FOXO1 fusion positive rhabdomyosarcoma$482,175
R01 · FY2024 · CA · contact PI
Defining and targeting ER quality control dependence in rhabdomyosarcoma$228,786
K08 · FY2022 · CA · contact PI
Defining and targeting ER quality control dependence in rhabdomyosarcoma$228,786
K08 · FY2021 · CA · contact PI
Defining and targeting ER quality control dependence in rhabdomyosarcoma$228,570
K08 · FY2020 · CA · contact PI
Defining and targeting ER quality control dependence in rhabdomyosarcoma$228,786
K08 · FY2019 · CA · contact PI
Defining and targeting ER quality control dependence in rhabdomyosarcoma$228,767
K08 · FY2018 · CA · contact PI